# US 2017/0283481 A1 · Engineered Invariant Natural Killer T (iNKT) Cells and Methods of Making and Using Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283481 A1
- Document ID: US20170283481A1
- Status: Published application
- Kind: A1
- Application number: 15/320,037
- Filed: 2015-07-08
- Published: 2017-10-05
- Earliest claimed: 2014-07-09
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Lili Yang; Drake J. Smith
- Web page: https://patentgrep.com/patent/US20170283481A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- A61K 40/4271: {Melanoma antigens}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 14/70503: {Immunoglobulin superfamily}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2239/57: Skin; melanoma
- C12N 2506/11: from blood or immune system cells
- C12N 2510/00: Genetically modified cells
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof. Specifically, the engineered cells iNKT are genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule. Further disclosed are iNKT TCR nucleotide sequences and codon optimized sequences for expression.

## Claims

### Claim 1

An engineered cell which is a cell genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule.

### Claim 2 (depends on 1)

The engineered cell of claim 1, wherein the cell is a hematopoietic stem cell or a hematopoietic progenitor cell.

### Claim 3 (depends on 1)

The engineered cell of claim 1, wherein the cell is a human cell.

### Claim 4 (depends on 1)

The engineered cell of claim 1, wherein the iNKT TCR nucleic acid molecule is a clone of a T cell receptor of an invariant natural killer T cell or has a sequence that has been modified from that of the T cell receptor of the invariant natural killer T cell.

### Claim 5 (depends on 1)

The engineered cell of claim 1, wherein the iNKT TCR nucleic acid molecule is a clone of a T cell receptor of a human invariant natural killer T cell or has a sequence that has been modified from that of the T cell receptor of the human invariant natural killer T cell.

### Claim 6 (depends on 1)

The engineered cell of claim 1, wherein the iNKT TCR nucleic acid molecule comprises a nucleic acid sequence obtained from a human iNKT T cell receptor.

### Claim 7 (depends on 1)

The engineered cell of claim 1, wherein the engineered cell lacks exogenous oncogenes.

### Claim 8 (depends on 1)

The engineered cell of claim 1, wherein the iNKT TCR nucleic acid molecule encodes a T cell receptor that recognizes α-galactosylceramide (α-GalCer) presented on CD1d.

### Claim 9 (depends on 1)

The engineered cell according to claim 1, wherein the engineered cell is a functional iNKT cell.

### Claim 10 (depends on 1)

A method of obtaining the engineered cell according to claim 1, which comprises transducing the cell with the at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule.

### Claim 11 (depends on 10)

The method of claim 10, which further comprises expanding the cell transduced with the iNKT TCR nucleic acid molecule in vitro.

### Claim 12 (depends on 10)

The method of claim 10, which further comprises engrafting the cell transduced with the iNKT TCR nucleic acid molecule in a subject to generate clonal populations of the engineered cell.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject contains human thymus tissue.

### Claim 14 (depends on 10)

The method of claim 10, which further comprises culturing the cell transduced with the iNKT TCR nucleic acid molecule with OP9-DL1 stromal cells and/or MS5-DL4 stromal cells and then culturing with CD1d-expressing dendritic cells or artificial antigen-presenting cells.

### Claim 15 (depends on 10)

The method of claim 10, which further comprises cloning the T cell receptor of the invariant natural killer T cell.

### Claim 16 (depends on 10)

The method of claim 10, wherein the iNKT TCR nucleic acid molecule is contained in an expression vector.

### Claim 17 (depends on 1)

A composition comprising one or more engineered cells according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 1)

A method of treating a subject in need of invariant natural killer T cells, which comprises administering to the subject the engineered cell according to claim 1 or a composition comprising the engineered cell.

### Claim 19 (depends on 18)

The method of claim 18, which further comprises administering to the subject an agent that stimulates invariant natural killer T cells to proliferate, release cytokines, and/or release chemokines.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the subject has a cancer, a bacterial infection, a viral infection, an allergy, or an autoimmune disease.
